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Edited by Gianni CesareniAbstract While negative eﬀect of smoking on the resistance to
viral infections was known, the underlying mechanisms remained
unclear. Here we report that products of cigarette smoking com-
promise the cellular anti-viral defenses by inhibiting the signaling
induced by Type I interferon (IFN). Cigarette smoking conden-
sate (but not pure nicotine) stimulated speciﬁc serine phosphory-
lation-dependent ubiquitination and degradation of the IFNAR1
subunit of the Type I IFN receptor leading to attenuation of IFN
signaling and decreased resistance to viral infection. This resis-
tance was restored in cells where phosphorylation-dependent deg-
radation of IFNAR1 is abolished. We conclude that smoking
compromises cellular anti-viral defenses via degradation of Type
I IFN receptor and discuss the signiﬁcance of this mechanism for
eﬃcacy of IFN-based therapies.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cigarette smoking poses numerous health risks including de-
creased resistance to viral infections. Although smoking was
shown to aﬀect the immune system [1], the speciﬁc mechanisms
of smokers sensitivity to viruses remain largely unknown.
Type I interferons (including IFNa and IFNb) emerged as
the major factors of anti-viral defense [2]. These cytokines
interact with a cognate receptor (consisting of IFNAR1 and
IFNAR2 chains) leading to activation of the Janus kinases
Tyk2 and Jak1. Ensuing tyrosine phosphorylation of signal
transducers and transcription activators (Stat1 and Stat2) sub-
sequently promotes expression of interferon-stimulated genes
(such as PKR and Stat1) whose products prevent viral replica-
tion and translation of viral proteins. Type II IFN (represented
by a single species, IFNc) also activates Stat1 and Jak1/2 ki-
nases but functions via entirely diﬀerent receptor (IFNGR1/*Corresponding author. Address: Department of Animal Biology,
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doi:10.1016/j.febslet.2008.08.0132; reviewed in [2,3]). Due to their potent biological eﬀects,
IFNa/b are widely used for treatment of chronic viral infec-
tions, multiple sclerosis and some malignancies including mel-
anoma [2].
Several studies have reported the inhibitory eﬀects of smok-
ing on immune responses that are known to be regulated by
Type I IFN [4–8]. For example, the levels of Th1 cells are de-
creased in the airways of smokers [8] indicating potential
immunosuppression. Furthermore, the epidemiologic data
indicate that smoking might decrease therapeutic beneﬁts of
IFN therapy in patients with hepatitis C [9] and promote pro-
gression of multiple sclerosis despite IFN treatment [10].
Although these observations point to the inhibitory eﬀects of
smoking on Type I IFN functions, the mechanisms underlying
negative regulation of IFN pathway by smoking products are
yet to be determined.
Here we report the inhibitory eﬀects of cigarette smoking
products on IFN signaling and function in cultured cells and
demonstrate that these products (but not pure nicotine) stimu-
late phosphorylation-dependent ubiquitination and downregu-
lation of the IFNAR1 chain of IFNa/b receptor. This
downregulation of IFNAR1 is essential in mediating the abil-
ity of smoking products to impede the signaling induced by
Type I IFN and to attenuate the cellular defenses against viral
infection.2. Materials and methods
2.1. Reagents
Recombinant murine IFNb and IFNc were purchased from PBL
laboratories. Cigarette smoke condensate extract (CSCE) was pre-
pared for a fee by Murty Pharmaceuticals Inc. (Lexington, KY) using
a Phipps-Bird 20-channel smoking machine and Kentucky standard
cigarettes (1R3F; University of Kentucky, Lexington, KY) as exten-
sively described elsewhere [11,12]. Brieﬂy, the particulate matter from
cigarette smoke was collected on Cambridge glass ﬁber ﬁlters, dis-
solved in dimethyl sulfoxide (DMSO) to yield a 4% solution (w/v)
and stored at 80 C. Nicotine and N-acetyl-L-cysteine (NAC) were
purchased from Sigma.
2.2. Cell lines, plasmids, and virus
Flag-tagged mIFNAR1wt (WT) and mIFNAR1S526A (SA) expres-
sion vectors were described previously [13]. These vectors were used
for stable reconstitution of IFNAR1 expression in cells derived from
IFNAR1 knockout mice. IFNAR1 null mouse embryo ﬁbroblasts
(MEFs, a gift from S. Hemmi, Institute for Molecular Biology, Zurich,
Switzerland) were transduced using the pBABE-puro-based retroviral
vectors (either empty or encoding Flag-tagged mIFNAR1wt orblished by Elsevier B.V. All rights reserved.
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deﬁcient)-derivative cell lines harboring either WT or kinase-dead
(KR) forms of Tyk2 [14] were kindly provided by Sandra Pellegrini
(Institut Pasteur, Paris, France). Human 293T and HeLa cells were ob-
tained from Z. Ronai (Burnham Institute, San Diego, CA, USA). All
cells were maintained in Dulbeccos modiﬁed Eagles medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum (Hyclone)
and either puromycin (3 lg/ml, for transduced MEFs) or G418
(400 lg/ml, for 11,1 derivatives) at 37 C in 5% CO2. Vesicular stoma-
titis virus (VSV, Indiana serotype) was propagated in HeLa cells.
2.3. Cell treatment and viral infection/titer measurement
The ﬁnal concentration of CSCE used in all described experiments
was 0.04% (corresponding nicotine concentration was equal to
22 ± 3 ng/ml). Cells were treated with CSCE, nicotine or respective
vehicle (DMSO or ethanol) for 0–2 h as indicated and then processed
for analysis of status of IFNAR1 or of elements of IFN signaling path-
way or of anti-viral resistance. For example, to examine the eﬀect of
CSCE on IFN-induced anti-viral state, CSCE-pretreated cells were
then pulse-treated (or not) with IFN for 1 h. Then IFN was removed
and the cells were incubated for 16 h in fresh medium. Then cells were
inoculated with VSV (at MOI 0.1) for 1 h followed by washing the
virus oﬀ and further incubation for 16 h. After that, the virus contain-
ing supernatant was harvested and collected to measure viral titer (as
described in [15]), while whole cell extracts were prepared for analysis
of cellular and viral proteins. VSV titer determination was performed
using a standard plaque assay [15]. Plaques were counted, multiplied
by dilution factor and presented as plaque-forming units (pfu)/
ml ± S.D. from three independent experiments (each in triplicate).
Immunotechniques were carried out as previously described [13,16].
Antibodies against pSTAT1, ERK1/2, eIF2a (Cell Signaling), phos-
pho-Ser535 (or phospho-Ser526 in murine receptor) [16], IFNAR1,
PKR, STAT1 (Santa Cruz), Flag, b-actin (Sigma) and ubiquitin (clone
FK2, Biomol) were used for immunoprecipitation (IP) and immuno-
blotting (IB) as described elsewhere [13,16]. Monoclonal antibody
23H12, speciﬁc for the M protein of VSV (VSV-M), was kindly pro-
vided by D.S. Lyles (Wake Forest University, Winston-Salem, NC).IF
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Fig. 1. Cigarette smoke condensate extract (CSCE) inhibits Type I IFN-ind
were pre-treated with CSCE for 1.5 h. After removal of CSCE, cells were pu
16 h. After that, cells were exposed to VSV for 1 h, washed and incubated in
VSV replication as described in material and methods. VSV titers are shown
MEFs treated as described in panel A were analyzed by immunoblotting (I
(normalized to the levels of total Erk) were quantitated as fold increase over
CSCE for 1.5 h and then with mIFNb (75 IU/ml) or mIFNc (5 ng/ml) for 30
panel). The amount of STAT1 is also shown as loading control (bottom pan3. Results and discussion
We ﬁrst investigated whether the products of cigarette
smoke can aﬀect the anti-viral defenses and Type I IFN signal-
ing in cultured cells infected with vesicular stomatitis virus
(VSV). Pre-treatment of mouse embryo ﬁbroblasts (MEFs)
with cigarette smoke condensate extract (CSCE) decreased
either inherent (naı¨ve cells) or exogenous IFNb-induced resis-
tance to this infection (Fig. 1A). Accordingly, CSCE-pre-
treated cells contained a higher level of a viral matrix
protein, VSV-M (Fig. 1B) indicating that smoking products in-
deed decreased the resistance of cells to VSV. Remarkably, no
eﬀect of CSCE was observed in MEFs derived from IFNAR1
knockout mice (Fig. 1A) suggesting that smoking products ap-
pears to speciﬁcally weaken the anti-viral defenses that are
mediated by IFNAR1 and Type I IFN.
Consistent with this possibility, pre-treatment of cells with
CSCE decreased either basal or IFN-induced levels of STAT1
and, to a lesser extent, PKR (Fig. 1B). In addition, cells pre-
treated with CSCE exhibited a dramatic decrease of IFNb-in-
duced tyrosine phosphorylation of Stat1. Remarkably, in
contrast to its eﬀect on Type I IFN signaling, CSCE elicited
only a modest eﬀect on Stat1 phosphorylation induced by
IFNc (Fig. 1C). Because IFNb and IFNc engage diﬀerent cog-
nate receptors yet both activate the Jak-Stat pathway, the lat-
ter result suggests that cigarette smoke products may
speciﬁcally target Type I IFN receptor.
As Type I IFN receptor levels are regulated by protein sta-
bility of IFNAR1 [13], we next examined the eﬀect of CSCE
on IFNAR1. Treatment of cells with CSCE downregulated IF-N - β - β - γ - γ
E - + - +
T1
T1
B
uced signaling and anti-viral defense. (A) MEFs (WT or IFNAR1/)
lse-treated with 10 IU/ml of mIFNb for 1 h, washed and incubated for
a fresh medium. At 15 h post-infection, supernatants were analyzed for
(pfu/ml) ± S.D. *P < 0.05 in the Students t-test. (B) Extracts from WT
B) using the indicated antibodies. Levels of STAT1 and PKR signals
the signals seen in untreated cells. (C) WT MEF cells were treated with
min. Activation of STAT1 was monitored by pSTAT1 antibody (top
el).
CSCE + +- - -
pStat1
Vector WT SA
IFNβ + + + + +- - - - -
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somal inhibitor methylamine HCl (MA). Furthermore, IF-
NAR1 immunopuriﬁed from cells treated with both MA and
CSCE exhibited an increase in the levels of its ubiquitination
(Fig. 2A). These data suggest that smoking products promote
ubiquitination and lysosomal degradation of IFNAR1.
We have previously demonstrated that ubiquitination and
degradation of IFNAR1 is controlled via phosphorylation of
IFNAR1 within its destruction motif on Ser535 (Ser526 in
mouse IFNAR1) that leads to IFNAR1 ubiquitination, endo-
cytosis and lysosomal degradation [13,16,17]. This phosphory-
lation could proceed via either ligand- and Tyk2-dependent
[14] or independent [18] pathway. We have next tested the ef-
fect of CSCE on IFNAR1 degron phosphorylation. Treatment
with CSCE increased Ser526/535 phosphorylation in both
mouse and human cells (Fig. 2B and C). The latter eﬀect did
not require Tyk2 catalytic activity, as it was still present in cells
that harbor only catalytically inactive Tyk2 ([14], Fig. 2C),
suggesting that CSCE promotes IFNAR1 phosphorylation
via the recently discovered ligand-independent pathway [18].
To determine whether CSCE-mediated downregulation of
IFNAR1 accounts for its eﬀect on IFN signaling and function,
we examined the eﬀect of CSCE on IFNb-induced signaling,
ISG expression, and anti-viral eﬀects in IFNAR1-null MEF
reconstituted with either wild-type receptor (WT cells) or IF-
NAR1S526A mutant (SA cells). Mutant IFNAR1S526A did not
undergo CSCE-mediated phosphorylation and was less sensi-IP: 
Flag
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CSCE - + - + +-
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Fig. 2. CSCE promotes phosphorylation-dependent ubiquitination
and lysosomal degradation of IFNAR1 in a Tyk2-independent
manner. (A) 293T cells were pre-incubated with or without lysosomal
pathway inhibitor methylamine–HCl (20 mM) for 1 h and then treated
with CSCE for 2 h. IFNAR1 was immunoprecipitated (IP) with anti-
IFNAR1 and analyzed by immunoblotting using the anti-Ub (top
panel) and anti-IFNAR1 (middle panel) antibodies. Levels of b-actin
in the extracts are shown as a loading control (bottom panel). (B)
IFNAR1/ MEF cells were stably reconstituted with either empty
vector (Vec), or vectors for expression of wild-type mouse Flag-
IFNAR1 (WT) or IFNAR1S526A mutant (SA). These cells were treated
with CSCE for 30 min and IFNAR1 proteins were immunopuriﬁed by
IP using anti-Flag antibody and analyzed by immunoblotting using
anti-ubiquitin, anti-pSer526, and anti-Flag antibodies as indicated.
Levels of b-actin in the aliquots of whole cell extracts are shown as a
loading control (bottom panel). (C) 11,1-derivative human cells that
express either wild-type Tyk2 (WT) or the kinase-dead Tyk2 (KR)
were treated with CSCE for 30 min. Endogenous IFNAR1 was
immunoprecipitated and analyzed by immunoblotting using anti-
pSer535 (top panel) or anti-IFNAR1 (bottom panel) antibodies.tive to CSCE-induced ubiquitination (Fig. 2B) and downregu-
lation (Fig. 3A, lower panel) than wild-type mouse receptor.
While pretreatment of WT cells with CSCE decreased the ex-
tent of IFNb-induced Stat1 phosphorylation, this eﬀect was
not pronounced in SA cells that express the ubiquitination-
deﬁcient IFNAR1S526A (Fig. 3A) suggesting that the smoking
products inhibit Type I IFN signaling via phosphorylation-
dependent degradation of IFNAR1.
Consistent with the latter hypothesis, expression of IF-
NAR1S526A mutant prevented a CSCE-mediated inhibition
of PKR expression (Fig. 3B). Furthermore, CSCE decreased
the anti-viral eﬀects of IFNb against VSV in cells expressing
wild-type IFNAR1 but not ubiquitination-deﬁcient IFNAR1-
S526A mutant (Fig. 3B, lower panel). Collectively, these data
indicate that cigarette smoking products inhibit IFN-mediated
anti-viral defenses via inducing phosphorylation-dependent
ubiquitination and downregulation of IFNAR1.
Our results demonstrate that smoking products promote IF-
NAR1 degron phosphorylation and downregulate IFNAR1 in
cells. Downregulation of IFNAR1 represents a novel mecha-PKR IFNβ
16 hr
β-actin
Vector WT SA
CSCE + ++- - -
IFNβ + + + + ++- - - - - -
1 2 3 4 5 6 7 8 9 10 11 12
IFNβ
0.5 hr
Stat1
Flag
fold 1.0 1.00.4 0.9
Fig. 3. CSCE requires phosphorylation-dependent downregulation of
IFNAR1 to impede the IFN signaling and anti-viral defense. (A) MEF
cells described in Fig. 2B were pretreated with CSCE for 2 h and then
stimulated with mIFNb (75 IU/ml) for 30 min. Activation of STAT1
was monitored by pSTAT1 antibody (top panel). The amounts of
STAT1 (middle panel) and Flag-IFNAR1 are shown (bottom panel).
Signal intensity of pSTAT1 was quantitated and normalized to the
levels of total STAT1. Relative activation levels of STAT1 are shown
(as fold-increase over cells that did not receive CSCE). (B) MEF cells
(described in Fig. 2B) were pre-treated with CSCE for 1 h and then
pulse-treated with of mIFNb (10 IU/ml) for 1 h. At 16 h post-mIFNb
pulse, cells were either analyzed for PKR and b-actin levels (upper
panels) or infected with VSV for 1 h (lower panel). At 24 h post-
infection, supernatants were analyzed for VSV replication (titer
depicted in lower panel) as described in the legend to Fig. 1A.
*P < 0.05.
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CSCE. This mechanism is likely to play an important role in a
decreased resistance of smokers to viral infections. Given that
a major immunomodulatory eﬀect of Type I IFN is to promote
T-cell diﬀerentiation toward Th1 phenotype, it is not surpris-
ing that levels of Th1 cells are decreased in the airways of
smokers [8]. Furthermore, our results might explain why the
eﬃcacy of IFNa therapy against hepatitis C is decreased in
smoking patients [9]. Intriguingly, when the cells received
equivalent or even higher doses of pure nicotine instead of
CSCE, neither degradation-inducing phosphorylation of IF-
NAR1 (Fig. 4A) nor suppression of anti-viral defenses
(Fig. 4B) were observed. This result suggests that, in addition
to smoking cessation, the nicotine replacement therapy might
be recommended for the smoker patients that undergoIP: R1
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Fig. 4. ROS (but not nicotine) contribute to CSCE-induced IFNAR1
phosphorylation. (A) 293T cells were treated with CSCE or indicated
amounts of nicotine for 30 min. Phosphorylation of IFNAR1 was
analyzed as in Fig. 2C. (B) Wild-type MEFs were pre-treated with
CSCE or nicotine (25 ng/ml or 100 ng/ml) for 1.5 h and then pulsed
with mIFNb (20 IU/ml) for 1 h. At 16 h post-mIFNb pulse, cells were
infected with VSV. At 24 h post-infection, supernatants were analyzed
for VSV replication using a standard plaque assay as described in panel
1A. (C) 293T cells were pretreated with or without 2.5 mM NAC for
1 h and subsequently stimulated with CSCE for 30 min. Phosphory-
lation of IFNAR1 was analyzed as in Fig. 2C. Levels of b-actin in the
whole cell extracts are shown as a loading control (bottom panel).IFNa/b treatment against chronic viral infections, multiple
sclerosis, and malignant melanoma.
How do products of cigarette smoking promote IFNAR1
phosphorylation? Cigarette smoke has been documented to
generate reactive oxygen species (ROS) that mediates a major
portion of its biological eﬀects and was shown to contribute to
inhibition of IFN signaling [19]. Therefore, we next investi-
gated whether ROS play a role in CSCE-induced phosphoryla-
tion of IFNAR1 using an inhibitor of ROS, N-acetylcysteine
(NAC). Pre-treatment of cells with this antioxidant noticeably
reduced CSCE-induced phosphorylation of IFNAR1
(Fig. 4C). While we cannot rule out other mechanisms by
which NAC may aﬀect the IFN signaling, our current result
indicates that ROS is a major mediator of CSCE-mediated IF-
NAR1 phosphorylation that leads to its degradation and im-
paired signaling. Further studies to delineate the molecular
mechanisms underlying ligand-independent phosphorylation,
ubiquitination and degradation of IFNAR1 and how these
events are stimulated by cigarette smoking products and med-
iated by ROS should contribute to developing strategies for
improving the therapeutic use of IFN.
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